This book is oriented towards post-graduates and researchers with interest in proteomics and its applications in clinical biomarker discovery pipeline. Biomarker discovery has long been the research focus of many life scientists globally. However, the pipeline starting from discovery to validation to regulation as a diagnostic or therapeutic molecule follows a complex trajectory. This book aims to provide an in-depth synopsis on each of these developmental phases attendant to biomarker “life cycle” with emphasis on the emerging and significant role of proteomics. The book begins with a perspective on the role of biorepositories and need for biobanking practices in the developing world. The next chapter focuses on disease heterogeneity in context to geographical bias towards susceptibility to the disease and the role of multi-omics techniques to devise disruptive innovations towards biomarker discovery. Chapter 3 focuses on various omics-based platforms that are currently being used for biomarker discovery, their principles and workflow. Mass spectrometry is emerging as a powerful technology for discovery based studies and targeted validation. Chapter 4 aims at providing a glimpse of the basic workflow and considerations in mass spectrometry based studies. Rapid and aptly targeted research funding has often been deemed as one of the decisive factors enabling excellent science and path breaking innovations. With the need for sophistication required in multi-omics research, Chapter 5 focuses on innovative funding strategies such as crowdfunding and Angel philanthropy. Chapter 6 provides the latest advances in education innovation, the premise and reality of bioeconomy especially in a specific context of the developing world, not to mention the new concept of “social innovation” to link biomarkers with socially responsible and sustainable applications. Chapter 7, in ways similar to biomarkers, discusses the biosimilars as a field that has received much focus and prominence recently due to their immense potential in clinical and pharmaceutical innovation literatures. The broader goal post-biomarker discovery is to translate their use in clinics. However, the road from bench-to-bed side is arduous and complex that is subject to oversight from various national and international regulatory bodies. Chapter 8 underscores these regulatory science considerations and provides a concise overview on intellectual property rights in biomarker discovery. Thus, this book contributed by eminent biomarker scientists, clinicians, translational researchers and social scientists holistically covers the various facets of the biomarker discovery journey from “cell to society” in developing world. The lessons learned and highlighted here are of interest to the life sciences community in a global and interdependent world.

The 'bioeconomy' is the idea of an economy based on the sustainable exploitation of biological resources. Within this concept, there is increasing emphasis on issues such as climate change, depletion of natural resources and growing world food needs. The bioeconomy builds on the recognition of advances in technology, particularly in the life sciences, but at the same time covers issues such as innovation management, ecosystem services, development and governance. This book explores the development of the bioeconomy across the world from an economic and policy perspective, as well as identifying potential future pathways and issues. It uses a broad definition, covering all sectors using biological resources except health, and rather than focusing on individual sectors, it explores the breadth of interconnections that make the bioeconomy a new and challenging subject. Divided into two parts, the book initially outlines the current definitions, strategies, policy and economic information related to the world's bioeconomy. The second part describes current economic analysis and research efforts in qualifying and understanding the economics of the bioeconomy. This includes the contributions of technology, research and innovation; driving forces and demand-side economics; supply-side economics, and the role of markets and public policy in matching demand and supply. The political economy, regulation and transitions are considered, as well as the contribution of the bioeconomy to society, including growth, development and sustainability. Key features include: - An analysis of varied international approaches to the bioeconomy. - A joint consideration of biotechnology, agriculture, food energy and bio-materials. - An assessment of sustainability in the bioeconomy. - A comprehensive view of the issues from an economic and policy perspective. This book will be of interest to students and researchers in agricultural and natural resource economics, agricultural and environmental policy, as well as policy-makers, practitioners and economists.

Agricultural Bioeconomy: Innovation and Foresight in the Post-COVID Era presents recent advancements in biotechnology, exploring the optimal utilization of technologies to provide rapid and impactful economic recovery and sustainable resources in a future that will bear the mark of COVID-19. Understanding that there is a necessary balance between risk and reward, this book provides a foundational hypothesis as well as operational direction for addressing the commercialization and regulatory issues in a bio-based economy where agricultural output is at the core. By presenting adaptable practices to successfully establish and progress agri-based global bioeconomies, the book features a new paradigm focused on technological foresight and response to future risks and disasters. Key considerations include assessing and managing the urban bioeconomy, climate change mitigation, biofuels and bioenergy, GMOs, and employment generation. This book provides the solid next step toward future-proofing global economies using a combination of agricultural technologies and economic goals. Professionals and advanced students focused on the production of renewable biological resources and their conversion into value-added products including food, feed, bio-based products, and bioenergy will find this book useful. Addresses recent issues emerging in agro-based economies Empowers utilization of biotechnology to address worldwide ecological issues Presents adaptable, risk-management approaches to the adoption of socially and financially valuable agri-based technologies

Many cancer patients are diagnosed at a stage in which the cancer is too far advanced to be cured, and most cancer treatments are effective in only a minority of patients undergoing therapy. Thus, there is tremendous opportunity to improve the outcome for people with cancer by enhancing detection and treatment approaches. Biomarkers will be instrumental in making that transition. Advances in biotechnology and genomics have given scientists new hope that biomarkers can be used to improve cancer screening and detection, to improve the drug development process, and to enhance the effectiveness and safety of cancer care by allowing physicians to tailor treatment for individual patients—an approach known as personalized medicine. However, progress overall has been slow, despite considerable effort and investment, and there are still many challenges and obstacles to overcome before this paradigm shift in oncology can become a reality.

Research has long sought to identify biomarkers that could detect cancer at an early stage, or predict the optimal cancer therapy for specific patients. Fueling interest in this research are recent technological advances in genomics, proteomics, and metabolomics that can enable researchers to capture the molecular fingerprints of specific cancers and fine-tune their classification according to the molecular defects they harbor. The discovery and development of new markers of cancer could potentially improve cancer screening, diagnosis, and treatment. Given the potential impact cancer biomarkers could have on the cost effectiveness of cancer detection and treatment, they could profoundly alter the economic burden of cancer as well. Despite the promise of cancer biomarkers, few biomarker-based cancer tests have entered the market, and the translation of research findings on cancer biomarkers into clinically useful tests seems to be lagging. This is perhaps not surprising given the technical, financial, regulatory, and social challenges linked to the discovery, development, validation, and incorporation of biomarker tests into clinical practice. To explore those challenges and ways to overcome them, the National Cancer Policy Forum held the conference "Developing Biomarker-Based Tools for Cancer Screening, Diagnosis and Treatment: The State of the Science, Evaluation, Implementation, and Economics" in Washington, D.C., from March 20 to 22, 2006. At this conference, experts gave presentations in one of six sessions. In addition, seven small group discussions explored the policy implications surrounding biomarker development and adoption into clinical practice. Developing Biomarker-based Tools for Developing Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics-Workshop Summary presents the conference proceedings and will be used by an Institute of Medicine (IOM) committee to develop consensus-based recommendations for moving the field of cancer biomarkers forward.

Genomic sequencing technologies have augmented the classification of cancer beyond tissue of origin and towards a molecular taxonomy of cancer. This has created opportunities to guide treatment decisions for individual patients with cancer based on their cancer’s unique molecular characteristics, also known as precision cancer medicine. The purpose of this text will be to describe the contribution and need for multiple disciplines working together to deliver precision cancer medicine. This entails a multi-disciplinary approach across fields including molecular pathology, computational biology, clinical oncology, cancer biology, drug development, genetics, immunology, and bioethics. Thus, we have outlined a current text on each of these fields as they work together to overcome various challenges and create opportunities to deliver precision cancer medicine. As trainees and junior faculty enter their respective fields, this text will provide a framework for understanding the role and responsibility for each specialist to contribute to this team science approach.

The definitive, complete reference of digital pathology! An extraordinarily comprehensive and complete book for individuals with anything from minimal knowledge to deep, accomplished experience in digital pathology. Easy to read and plainly written, Digital Pathology examines the history and technological evolution of digital pathology, from the birth of scanning technology and telepathology to three-dimensional imaging on large multi-touch displays and computer aided diagnosis. A must-have book for anyone wishing to learn more about and work in this exciting and critical information environment including pathologists, laboratory professionals, students and any other medical practitioners with a particular interest in the history and future of digital pathology. It can also be a useful reference for anyone, medical or non-medical, who have an interest in learning more about the field. Digital pathology is truly a game changer, and this book is a crucial tool for anyone wishing to know more. Subjects discussed in depth include: Static digital imaging; basics and clinical use. Digital imaging processes. Telepathology. While slide imaging. Clinical applications of whole slide imaging. Digital pathology for educational, quality improvement, research and other settings. Forensic digital imaging.